Načítá se...
Autotaxin in Pathophysiology and Pulmonary Fibrosis
Lysophospholipid signaling is emerging as a druggable regulator of pathophysiological responses, and especially fibrosis, exemplified by the relative ongoing clinical trials in idiopathic pulmonary fibrosis (IPF) patients. In this review, we focus on ectonucleotide pyrophosphatase-phosphodiesterase...
Uloženo v:
| Vydáno v: | Front Med (Lausanne) |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Frontiers Media S.A.
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6008954/ https://ncbi.nlm.nih.gov/pubmed/29951481 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmed.2018.00180 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|